Klaria Interim Report Q3 2020
Klaria Interim Report Q3 2020Summary of the period Two new clinical programs initiated, first license agreement signed inthe medical cannabis segment THIRD QUARTER 2020 (JULY–SEPTEMBER) Net sales amounted to 0.0 MSEK (0.1 MSEK) R&D costs for the period amounted to 13.6 MSEK (5.4 MSEK) Profit after tax amounted to -13.3 MSEK (-7.2 MSEK) Earnings per share for the quarter amounted to -0.28 SEK (-0.23 SEK) Cash flow from operating activities amounted to -12.2 MSEK (5.5 MSEK) Cash and cash equivalents on the balance day amounted to 19.3 MSEK (8.9 MSEK)